Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/301% below fair value
$9.61−0.62 (-6.06%)
Close on Nov 13, 2026Market cap $647.14MP/E –Yield –
Ginkgo Bioworks enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ginkgo Bioworks's enterprise value was $568.50M on Nov 11, 2026, against $31.96M a year earlier. Over the last 5 years it ranged from -$382.70M to $10.68B, with a median of $732.88M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $568.50M | – |
| 2025 | Dec 31, 2025 | -$23.17M | – |
| 2024 | Dec 31, 2024 | -$94.95M | -104.2% |
| 2023 | Dec 29, 2023 | $2.28B | +53.5% |
| 2022 | Dec 30, 2022 | $1.49B | -86.1% |
| 2021 | Dec 31, 2021 | $10.68B | – |
See a number that looks wrong?